Optimization of lead compounds into on-demand, nonhormonal contraceptives: leveraging a public-private drug discovery institute collaboration.
Biol Reprod
; 103(2): 176-182, 2020 08 04.
Article
em En
| MEDLINE
| ID: mdl-32307523
ABSTRACT
Efforts to develop new male or female nonhormonal, orally available contraceptives assume that to be effective and safe, targets must be (1) essential for fertility; (2) amenable to targeting by small-molecule inhibitors; and (3) restricted to the germline. In this perspective, we question the third assumption and propose that despite its wide expression, soluble adenylyl cyclase (sAC ADCY10), which is essential for male fertility, is a valid target. We hypothesize that an acute-acting sAC inhibitor may provide orally available, on-demand, nonhormonal contraception for men without adverse, mechanism-based effects. To test this concept, we describe a collaboration between academia and the unique capabilities of a public-private drug discovery institute.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Anticoncepcionais
/
Descoberta de Drogas
Limite:
Humans
Idioma:
En
Revista:
Biol Reprod
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos